Last C$8.16 CAD
Change Today -0.03 / -0.37%
Volume 13.0K
COM On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 3:59 PM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

cardiome pharma corp (COM) Snapshot

Open
C$8.06
Previous Close
C$8.19
Day High
C$8.21
Day Low
C$8.05
52 Week High
02/14/14 - C$12.02
52 Week Low
09/17/13 - C$2.46
Market Cap
134.8M
Average Volume 10 Days
23.2K
EPS TTM
C$-1.35
Shares Outstanding
16.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARDIOME PHARMA CORP (COM)

Related News

No related news articles were found.

cardiome pharma corp (COM) Related Businessweek News

No Related Businessweek News Found

cardiome pharma corp (COM) Details

Cardiome Pharma Corp., a biopharmaceutical company, is engaged in the development and commercialization of cardiovascular therapies that enhance the life and health of patients. It offers BRINAVESS (vernakalant IV), for conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company’s pre-clinical research and development focuses on modulating cellular proteins (ion channels) that gate the movement of ions across the cell membrane to control various functions, including contraction of muscles, secretion from glands, and responses to foreign bodies and inflammation. It has operations in Canada, the United States, Switzerland, and the United Kingdom. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

75 Employees
Last Reported Date: 03/27/14
Founded in 1986

cardiome pharma corp (COM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$508.3K
Chief Financial Officer
Total Annual Compensation: C$250.2K
Chief Operating Officer
Total Annual Compensation: C$220.3K
Chief Commercial Officer
Total Annual Compensation: C$390.0K
Corporate General Counsel
Total Annual Compensation: C$206.0K
Compensation as of Fiscal Year 2013.

cardiome pharma corp (COM) Key Developments

Cardiome Pharma Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Cardiome Pharma Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenues were $7.667 million against $0.107 million a year ago. Operating loss was $4.007 million against $2.953 million a year ago. Net loss before income taxes was $4.084 million against $2.774 million a year ago. Net loss was $4.240 million or $0.26 per basic and diluted share against $2.774 million or $0.22 per basic and diluted share a year ago. Net cash used in operating activities were $3.328 million against $6.042 million a year ago. Purchase of property and equipment was $0.014 million against $0.013 million a year ago. Purchase of intangible assets was $0.040 million against $0.022 million a year ago. For the six months, total revenues were $15.259 million against $0.167 million a year ago. Operating loss was $6.688 million against $5.534 million a year ago. Net loss before income taxes was $7.101 million against net income before income taxes of $15.619 million a year ago. Net loss was $7.374 million or $0.46 per basic and diluted share against net income of $15.619 million or $1.25 per basic and diluted share a year ago. Net cash used in operating activities were $12.624 million against $8.524 million a year ago. Purchase of property and equipment was $0.017 million against $0.013 million a year ago. Purchase of intangible assets was $0.052 million against $0.040 million a year ago.

Cardiome Pharma Mulls Financing

Cardiome Pharma Corp. (TSX:COM) is looking for cash injection. Jennifer Archibald, Chief Financial Officer of Cardiome Pharma Corp. said, "We intend to seek additional financing to support our expansion and development activities, such as to support acquisition of products, work related to advancing our vernakalant IV program in the US and our vernakalant oral program."

Cardiome Pharma Corp. to Report Q2, 2014 Results on Aug 11, 2014

Cardiome Pharma Corp. announced that they will report Q2, 2014 results at 12:01 PM, US Eastern Standard Time on Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COM:CN C$8.16 CAD -0.03

COM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COM.
View Industry Companies
 

Industry Analysis

COM

Industry Average

Valuation COM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.2x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOME PHARMA CORP, please visit www.cardiome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.